Table of Contents Table of Contents
Previous Page  264 / 812 Next Page
Information
Show Menu
Previous Page 264 / 812 Next Page
Page Background

S260

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

school-based universal prevention program for enhancing emo-

tional coping abilities with others’ emotions, which was imple-

mented in eight classes during onemonth. The questionnaires were

utilized for assessing implicit positive and negative affect (IPA and

INA), explicit emotional coping abilities to identify, understand, and

regulate others’ emotions, and the adaptive status of children at

school.

Results

Hierarchical regression analyses showed that higher IPA

at T1 was associated with higher explicit emotional coping and

motivation for learning at T2. Also, higher INA at T1 was related

to better peer relationship at T2. Moreover, higher IPA and INA at

T1 were concerned with higher scores of classroom climate and

approval at T2.

Conclusion

This study suggested that higher IPA leads to higher

explicit emotional coping with others’ emotions. Also, it suggested

that higher implicit affectivity (i.e., both higher IPA and INA) causes

more adaptive status of children at school.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.534

Psychoneuroimmunology

EW417

Oxidative DNA damage is associated

with antidepressant use, not

depression or anxiety disorders

C. Black

1 ,

, M. Bot

1

, P. Scheffer

2

, B. Penninx

1

1

VU University Medical Center, Psychiatry/GGZ inGeest, Amsterdam,

Netherlands

2

VU University Medical Center, Clinical Chemistry, Amsterdam,

Netherlands

Corresponding author.

Introduction

Oxidative stress has been implicated in the patho-

physiology of depression and anxiety disorders and may be

influenced by antidepressant use.

Objectives

This study investigated the association of oxidative

stress, measured by plasma levels of F2-isoprostanes and 8-

hydroxy-2 -deoxyguanosine (8-OHdG), reflecting oxidative lipid

and DNA damage respectively, with major depressive disorder

(MDD), generalized anxiety disorder, social phobia, panic disorder,

agoraphobia and antidepressant use in a large cohort.

Methods

Data was derived from the Netherlands Study of

Depression and Anxiety including patients with current (

n

= 1641)

or remitted (

n

= 610) MDD and/or anxiety disorder(s) (of which

n

= 709 antidepressant users) and 633 controls. Diagnoses were

established with the Composite Interview Diagnostic Instru-

ment. Plasma 8-OHdG and F2-isoprostanes were measured using

UHPLC-MS/MS. ANCOVA was performed adjusting for sampling,

sociodemographic, health and lifestyle variables.

Results

F2-isoprostanes did not differ between controls and

patients, or by antidepressant use. Patients (current or remit-

ted) using antidepressants had lower 8-OHdG (adjusted mean

38.3 pmol/L) compared to patients (current or remitted) without

antidepressants (44.7 pmol/L) and controls (44.9 pmol/L,

P

< 0.001;

Cohen’s

d

0.26). Findings for 8-OHdGwere similar over all disorders

and all antidepressant types (SSRIs, TCAs, SNRIs;

P

< 0.001).

Conclusion

Contrary to previous findings this large-scale study

didnot find increased oxidative stressmeasured by F2-isoprostanes

or 8-OHdG in MDD or anxiety disorders. 8-OHdG levels were lower

in antidepressant users, which suggests antidepressants may have

antioxidant properties.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.535

EW418

Antioxidant uric acid is lower in

current major depression and anxiety

disorders

C. Black

1 ,

, M .

Bot

1 , P. S

cheffer

2 , B. P

enninx

1

1

VU University Medical Center, Psychiatry/GGZ inGeest, Amsterdam,

Netherlands

2

VU University Medical Center, Clinical Chemistry, Amsterdam,

Netherlands

Corresponding author.

Introduction

It has been hypothesized that lowered antioxidant

capacity, which leads to increased oxidative stress, may be involved

in the pathophysiology of major depressive disorder (MDD) and

anxiety disorders and might be altered by antidepressant treat-

ment.

Objectives

This study investigated the association of plasma uric

acid, the greatest contributor to blood antioxidant capacity, with

MDD, generalized anxiety disorder, social phobia, panic disorder,

agoraphobia and antidepressants in a large cohort.

Methods

Data was derived from the Netherlands Study of

Depression and Anxiety including patients with current (

n

= 1648)

or remitted (

n

= 609) MDD and/or anxiety disorder(s) (of which

n

= 710 antidepressant users) and 618 controls. Diagnoses were

established with the Composite Interview Diagnostic Instrument.

Symptom severity was ascertained in all participants with the

Inventory of Depressive Symptoms and the Beck Anxiety Inventory.

ANCOVA and regression analyses were adjusted for sociodemo-

graphic, health and lifestyle variables.

Results

Plasma uric acid was lower in those with current MDD

and/or anxiety disorder(s) (adjusted mean 270 mol/L) compared

to those with remitted disorders (280 mol/L,

P

< 0.001) or to

controls (281 mol/L,

P

< 0.001; Cohen’s

d

0.14). Within patients

antidepressants were not associated with uric acid levels. Increas-

ing symptom severity was associated with lower uric acid levels

for both depression ( = –0.05,

P

= 0.001) and anxiety symptoms

( = –0.05,

P

= 0.004).

Conclusion

This large scale study finds that the antioxidant uric

acid is lower in current, but not remitted, MDD or anxiety disorders

and in persons with higher symptom severity, suggesting distur-

bances in redox homeostasis play a role in the pathophysiology of

depression and anxiety disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.536

EW419

Interleukin-receptor antagonist

(IL1-RA) with respect to schizophrenia

psychopathology

D. Frydecka

1 ,

, B . M

isiak

2 , P. S

edlaczek

3 , E. P

awlak-Adamska

4

1

Wroclaw Medical University, Department of Psychiatry, Wrocław,

Poland

2

Wroclaw Medical University, Department of Genetics, Wrocław,

Poland

3

Wroclaw Medical University, Department and Clinic of Gynaecology

and Obsterics, Wrocław, Poland

4

Institute of Immunology and Experimental Therapy, Polish Academy

of Science, Department of Experimental Therapy, Wrocław, Poland

Corresponding author.